Abstract:
Dyslipidaemia comprises of abnormal lipid components and refers mainly to increased levels of LDL, non HDL particles and triglycerides while decreased levels of HDL Dyslipidaemia is a common and independent modifiable risk factor for cardiovascular disease. Besides quantitative measurement, qualitative assessment of these components is also essential and therefore particles like Lipoprotein (a) and Apo-B should be taken into account.
Unlike in the past where dyslipidaemia was treated mainly based on their quantitative levels, there is a paradigm shift in providing a more personalized care to patients. This is based on assessment of cardiovascular risk of individual patient which allows choosing the right strategy of therapy for them. This would include using the right intensity statin therapy in the correct dose for a category or level of cardiovascular risk. In addition, there is now more emphasis on making use of other lipid lowering drugs like Ezetimibe, PCSK-9 Inhibitor, Fibrates and Omega 3 Fatty Acid. Adoption of these strategies are based on evidence derived from several well designed randomized control trials that have shown to lead to better cardiovascular outcome.
It is therefore vital that clinicians are aware of this concept of precision Medicine so that prescription for managing dyslipidaemia is more cost effective and lifesaving.
Biography:
Dr Syed Raza graduated from Aligarh University in India in 1993. After completing his postgraduate degree in Medicine from the same university, he moved to the UK for higher specialist studies. He successfully completed MRCP and CCT and later also awarded Fellow of the Royal College of Physicians of Edinburgh (FRCP ). He was awarded Professor John Goodwin prize for outstanding performance in Diploma Cardiology exam at Hammersmith Hospital, University of London in 2001. Dr Raza is Fellow of American College of Cardiology and American College of Chest Physicoans. He is also Fellow of European Society of Cardiology and Fellow of European Society of Cardiovascular Imaging. He is also on the committee of Acute Cardiovascular Care. Heart Failure and Cardiovascular Imaging (European Society of Cardiology).
He is currently working as Consultant Cardiologist and Head of the department of Medicine at Awali Hospital, Bahrain. Dr Raza is a board member of the Hospital Excecutive Committee. He also chairs the Resuscitation committee and Privileging and Credentialing Committee. Prior to this he worked as consultant in Cardiology at Mid Cheshire Hospitals, NHS trust, United Kingdom. He is the regional educational coordinator for RCP Edinburgh and examiner for MRCP exam for the Royal College of Physicians of UK. He has partipcpated in some well known trials and reasearch. He has to his credit numerous publications and he has presented his scietific work in different parts of the world. He is peer review author for some well respected International journals. He is permanent Review author for abstracts for European Society of Cardiology Annual Congress.
He is on the editorial board of International Journal of Endovasculat Treatment and Innovative Techniques. Dr Raza is a teaching faculty member for Healthcare Management and Leadership at Westford University, Dubai campus. He is certified American Board in Medical Quality. Dr Raza frequently organises a number of seminars, webinars, symposia and workshop on various healthcare, quality and safety topics. Dr Raza has led the first awareness campaign in Heart Failure in the Middle East in 2017. He is chairman of BAPCO's health promotion unit. His special interests are Cardiovascular Imaging, Heart Failure and Acute Cardiovascular Care. He is founder and chairman of Raza Foundations which works for educating and increasing awareness on various health related topics amongst the general public as well as provide free healthcare services to poor as one of the charity initiatives.
